| Title: | Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease |
| Journal: | JAMA Cardiol |
| Published: | 6 Oct 2020 |
| Pubmed: | https://pubmed.ncbi.nlm.nih.gov/33021622/ |
| DOI: | https://doi.org/10.1001/jamacardio.2020.5398 |
Publication 3724
WARNING: the interactive features of this website use CSS3, which your browser does not support. To use the full features of this website, please update your browser.
Abstract
Question Does measurement of lipoprotein(a) and/or LPA genetic risk score (GRS) have clinical utility in risk prediction of incident atherosclerotic cardiovascular disease (ASCVD)?Findings In this cohort of 283 540 adults recruited by the UK Biobank, both measured lipoprotein(a) and LPA GRS were associated with comparable risk of incident ASCVD events. The LPA GRS did not yield additional prognostic information beyond measured lipoprotein(a), and both measured lipoprotein(a) and LPA GRS yielded modest improvements in the discrimination of ASCVD risk relative to the Pooled Cohort Equations or QRISK3.
Meaning Cardiovascular risk assessment with lipoprotein(a) may be achieved with either direct measurement or an LPA GRS.
1 Author
- Trinder M et al.
1 Application
| Application ID | Title |
|---|---|
| 7089 | Exome Sequencing of All Premature Coronary Artery Disease Participants in UK Biobank |
Enabling scientific discoveries that improve human health